

#### **HEALTH PARTNERS PLANS** PRIOR AUTHORIZATION REQUEST FORM

### Apomorphine (Non-PDL)

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs	i) left blank, illegible, or not attac	ched WILL DELAY the review process.	
Patient Name:	Prescriber Name:		
HPP Member Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Patient Primary Phone:	NPI:	PA PROMISe ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Line of Business: ☐ Medicaid ☐ CHIP	Specialty Pharmacy (if applicable):		
Drug Name:	Strength:		
Quantity:	Refills:		
Directions:			
Diagnosis Code: Diagnosis:			
HPP's maximum approval time is 12 months but may be less depending on the drug.			
Please attach any pertinent medical history including labs and information for this member that may support approval.			
Please answer the following questions and sign.			
Q1. Is this a renewal request? If yes, go to 2. If not, go to 6.			
Q1. Is this a renewal request: If yes, go to 2. If hot, go to	00.		
☐ Yes	☐ Yes ☐ No		
Q2. Does the patient continue to need Apomorphine and meet the criteria identified for initial approval?			
☐ Yes ☐ No			
Q3. Does the patient tolerate the medication without significant or serious side effects (must attach documentation)?			
Yes	☐ Yes ☐ No		
Q4. Has the patient had an improvement in symptoms from baseline (must attach documentation)?			
☐ Yes	□ No		
Q5. Is there documentation of a treatment plan including duration of treatment (must attach documentation)?			
Yes	□ No		
Q6. Does the patient have a diagnosis of advance Parkinson's Disease (PD) with documented hypomobility "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) (documentation must be attached)?			
Yes	☐ No		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



## HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

### Apomorphine (Non-PDL)

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:	
Q7. Is the medication being prescribed by or in consultat or a neurologist)?	ion with a specialist (who specializes in the treatment of PD	
☐Yes	□ No	
Q8. Does the patient have a history of therapeutic failure, a contraindication to or intolerance of the preferred Antiparkinson's agents (such as carbidopa-levodopa, pramipexole, ropinirole, bromocriptine, amantadine, selegiline, trihexyphenidyl, benztropine,) (Must attach documentation)?		
☐Yes	□ No	
Q9. Will the initial "test" dose be given under medical supervision?		
☐Yes	□ No	
Q10. Will the medication ONLY be given via subcutaneous route of administration?		
☐Yes	□ No	
Q11. Will trimethobenzamide be started 3 days prior to the initial dose of Apomorphine, and continue as long as necessary to control nausea and vomiting (generally no longer than 2 months)?		
☐ Yes	□ No	
Q12. Will this medicine be administered with 5HT3 antag	gonists (such as ondansetron) to control nausea?	
☐Yes	□ No	
Q13. Has renal function been evaluated and has medica	tion been dose adjusted for renal impairment, if necessary?	
☐Yes	□ No	
Q14. Has a cardiac evaluation been performed (including assessment of QTc interval)?		
☐Yes	□ No	
Q15. Has the patient been counseled on the risks of usin medications while taking this medication	ng alcohol, antihypertensive medications, and vasodilating	
Yes	□ No	
Q16. Will the patient abstain from alcohol while taking this medicine?		

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document



# HEALTH PARTNERS PLANS PRIOR AUTHORIZATION REQUEST FORM

### Apomorphine (Non-PDL)

Phone: 215-991-4300 Fax back to: 866-240-3712

Health Partners Plans manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above.

PLEASE NOTE: Any information (patient, prescriber, drug, labs) left blank, illegible, or not attached WILL DELAY the review process.

Patient Name:	Prescriber Name:	
☐Yes	□No	
Q17. Is the treatment plan attached showing how the medication will be administered, duration of therapy, and other medications that will be continued?		
☐Yes	□No	
Q18. Is each dose less than or equal to 0.6 mL with a dosing frequency of less than or equal to five times per day?		
☐Yes	□No	
Q19. Additional Information:		
Prescriber Signature		

Updated for 2023